8-K: Calidi Biotherapeutics Stockholders Approve Reverse Stock Split and Multiple Share Issuance Proposals

Calidi Biotherapeutics' stockholders approved a reverse stock split and several proposals related to the issuance of common stock and warrants at a special meeting on June 6, 2024.

Summary

• Calidi Biotherapeutics held a Special Meeting of Stockholders on June 6, 2024, with 61.05% of outstanding shares represented.
• Stockholders approved a reverse stock split of the company's common stock at a ratio between 1-for-10 and 1-for-50, to be determined by the Board of Directors.
• The meeting also approved the issuance of Common Stock Units at $0.40 per unit related to the conversion of a $1.0 million convertible note.
• Additionally, the issuance of Common Stock Units at $0.40 per unit related to the conversion of a $2.0 million convertible note was approved.
• Stockholders approved the issuance of shares related to a $25.0 million Standby Equity Purchase Agreement, which could increase to $50.0 million.
• A proposal to adjourn the meeting to solicit additional proxies for the reverse stock split was also approved.

Sentiment

Score: 5

Explanation: The document reflects necessary corporate actions to maintain listing and secure funding, but the potential for dilution and the reverse stock split introduce some uncertainty. The sentiment is neutral to slightly negative.

Positives

• The approval of the reverse stock split gives the company flexibility to manage its share price.
• The approval of the share issuances related to the convertible notes provides the company with additional capital.
• The approval of the SEPA provides access to a significant amount of potential capital.

Negatives

• The reverse stock split could be perceived negatively by some investors.
• The issuance of new shares will dilute existing shareholders' ownership.
• The potential for significant share issuance under the SEPA could further dilute existing shareholders.

Risks

• The reverse stock split could negatively impact the stock price if not well received by the market.
• The issuance of new shares could lead to significant dilution of existing shareholders' ownership.
• The company's reliance on convertible notes and the SEPA for funding could indicate financial challenges.

Future Outlook

The company has the option to enact a reverse stock split at a ratio between 1-for-10 and 1-for-50. The company also has access to capital through the approved share issuances and the Standby Equity Purchase Agreement.

Management Comments

• The Board of Directors will determine the specific ratio for the reverse stock split.
• The company is proceeding with the share issuances related to the convertible notes and the Standby Equity Purchase Agreement.

Industry Context

The approval of these proposals is likely aimed at ensuring the company's continued listing on the NYSE American LLC and securing necessary funding for operations and growth. Reverse stock splits are often used by companies to maintain listing compliance or to make their stock more attractive to institutional investors.

Comparison to Industry Standards

• Reverse stock splits are a common tool for companies facing delisting from major exchanges, such as the NYSE American LLC, and are often seen in the biotechnology sector.
• The use of convertible notes and standby equity purchase agreements is a typical method for smaller biotech companies to raise capital, especially when traditional financing is difficult to obtain.
• The specific terms of the warrants and the pricing of the units are within the range of what is seen in similar transactions in the biotech industry.

Stakeholder Impact

• Shareholders will experience a reverse stock split, which may impact the share price.
• Shareholders will experience dilution due to the issuance of new shares.
• The company's ability to raise capital will be improved, which could benefit the company's long-term prospects.

Next Steps

• The Board of Directors will determine the specific ratio for the reverse stock split.
• The company will proceed with the issuance of shares and warrants related to the convertible notes.
• The company will proceed with the Standby Equity Purchase Agreement as needed.

Key Dates

Keywords

reverse stock split, common stock, stockholders meeting, share issuance, convertible note, warrants, standby equity purchase agreement, dilution, capital raise